CRO Expands for Global Reach
Quanticate Sets Out to Becomes a Major New Player in the Global CRO Market
QUANTICATE SETS OUT TO BECOME A MAJOR NEW PLAYER IN THE GLOBAL CRO MARKET
David Underwood, Chief Executive took advantage of the DIA conference in Boston to launch the Quanticate brand in the US market.
Quanticate is an integration of the strengths and capabilities of two longstanding and respected service providers to the pharmaceutical industry in Statwood and Oxford Pharmaceutical Sciences. After 5 years of close collaboration, the two companies have successfully completed a formal integration creating a single entity called Quanticate.
The company set up its first US operation in Boston in July 2007 in response to demand from its US based customers and the launch of Quanticate represents the first step in major expansion plans to expand the company’s capabilities and presence in the North American market.
With over 200 members of staff and nine offices on 3 continents, Quanticate already has the resources and capabilities of a global player and while providing the full range of CRO services has particular expertise in biometrics and medical writing.
The company has its own world class EDC / paper solution called ClinNav™ and is well known for its flexible approach to data collection and management and its ability to integrate with its customers own technology environments.
David Underwood commented: “The launch of Quanticate is a truly exciting moment in our history and provides the ideal springboard for our continued expansion into global and full service clinical research solutions and into the US market. We expect to add further capabilities over the coming months and Quanticate is a name and a company that we expect to grow rapidly in terms of its recognition as a leading player in our field.”
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
FDA-Approved Gene Therapy Beqvez Shows Sustained Efficacy, Safety in Long-Term Hemophilia B Trial
April 17th 2025Beqvez (fidanacogene elaparvovec), an FDA-approved one-time gene therapy for hemophilia B, demonstrated sustained factor IX expression, low bleeding rates, and a favorable safety profile over long-term follow-up.
